GlaxoSmithKline Pharmaceuticals Analysis (March) 2026

GlaxoSmithKline Phar...

BSE:500660

Rp 2.321,60

Rp0,00 (0,00%)

2.321,60 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

GlaxoSmithKline Pharmaceuticals Stock Value

According to analysts, the current valuation of BSE:500660 is Outperform.

Outperform

GlaxoSmithKline Pharmaceuticals Company Info

EPS Growth 5Y

15,35%

Market Cap

Rp393,29 B

Long-Term Debt

Rp0,00 B

Annual earnings

05/13/2026 (E)

Dividend

Rp42,02

Dividend Yield

1,81%

Founded

1924

Industry

Health Care

Country

India

Website

GlaxoSmithKline Pharmaceuticals

ISIN Number

INE159A01016

Website

http://india-pharma.gsk.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp3.029,00

30.47%

Last Update: 03/28/2026

Analysts: 4

Highest Price Target Rp3.500,00

Average Price Target Rp3.029,00

Lowest Price Target Rp2.700,00

In the last five quarters, GlaxoSmithKline Pharmaceuticals’s Price Target has risen from Rp2.484,81 to Rp2.617,75 - a 5,35% increase. Four analysts predict that GlaxoSmithKline Pharmaceuticals’s share price will increase in the coming year, reaching Rp3.029,00. This would represent an increase of 30,47%.

Top growth stocks in the health care sector (5Y.)

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline Pharmaceuticals Limited engaging in the development, manufacture, and marketing of pharmaceutical products. Business Segments. The Company operations into a singular reportable segment categorized as Pharmaceuticals. This classification stems from the internal reporting and strategic decision-making processes led by its Chief Operating Decision Maker (CODM). In essence, the CODM oversees resource allocation, assesses financial performance, and steers strategic initiatives direc...

GlaxoSmithKline Pharmaceuticals Limited engaging in the development, manufacture, and marketing of pharmaceutical products.

Business Segments.

The Company operations into a singular reportable segment categorized as Pharmaceuticals. This classification stems from the internal reporting and strategic decision-making processes led by its Chief Operating Decision Maker (CODM). In essence, the CODM oversees resource allocation, assesses financial performance, and steers strategic initiatives directly related to pharmaceuticals. The holistic approach allows for comprehensive evaluations of product lines and market trends, reinforcing the Company’s positioning within the industry.

The Company's commitment to pharmaceuticals extends to various subcategories, which may encompass generic medications, specialty pharmaceuticals, and over-the-counter products. This diversified approach within the pharmaceutical segment enables the company to address a vast array of healthcare needs, enhancing its market competitiveness and growth opportunities.

The Company stays abreast of scientific advancements, technology integrations, and regulatory standards. Besides traditional medicine development, the company is poised to invest in research initiatives that promote innovation in therapeutic solutions. This proactive stance allows the Company to maintain its relevance in an evolving market landscape, adapting to changing consumer preferences and regulatory demands.

Business Strategy

The company's business strategy focuses on sustainable growth through innovation, compliance with regulatory frameworks, and maintaining robust operational efficiencies. By prioritizing research and development, the company endeavors to introduce novel pharmaceutical products that meet unmet medical needs while adhering to stringent quality standards.

The company targets synergies that foster expansion into new territories and enhance its product offerings. By aligning with similar entities, The Company can leverage complementary strengths, expanding distribution networks and gaining access to additional resources.

The focus on patient-centric solutions is another cornerstone of the Company’s strategy. By understanding patient needs, The Company to tailor its products and services, ensuring they align with market expectations and improve patient outcomes.

Products and Services

The company’s portfolio comprises an extensive range of pharmaceuticals tailored for diverse market needs. The cornerstone of its offerings includes prescription medications, over-the-counter drugs, and medical devices. Each product line is developed with a focus on efficacy, safety, and quality, aligning with the highest industry standards.

The company focuses on critical therapeutic areas such as oncology, cardiology, neurology, and infectious diseases. By investing heavily in research and clinical trials, the company develops innovative therapies that help address significant health challenges.

Over-the-counter products represent a significant aspect of its portfolio, offering consumers greater accessibility to healthcare solutions for common ailments without the need for prescriptions. These products range from pain relief medications to nutritional supplements, catering to diverse demographics.

Additionally, The company offers consultative and educational services for healthcare professionals. By fostering strong relationships with healthcare practitioners, the company provides value beyond its products, equipping professionals with the knowledge to enhance patient care.

Geographical Markets

The company serves a broad geographical market to expand its footprint across multiple continents. Its operations are concentrated in major healthcare markets, including North America, Europe, and Asia-Pacific, each representing a significant portion of the global pharmaceutical landscape. The Company’s commitment to understanding local market dynamics and regulatory environments allows it to respond effectively to diverse consumer needs.

To foster growth, the company continuously evaluates entry into emerging markets, seeking opportunities where healthcare demand is growing, and regulatory frameworks are becoming favorable for pharmaceutical operations. This global perspective enables The company to capitalize on international growth opportunities while also establishing a robust supply-chain framework for seamless distribution.

Seasonality

The company’s operations can experience fluctuations that correlate with specific seasonal trends within the pharmaceutical sector. Generally, demand may increase during particular periods due to heightened seasonal illnesses, requiring the company to optimize inventory and production capabilities accordingly.

Moreover, regulatory approvals and product launches may align with specific periods in the year, contributing to variations in operational performance. As such, the company remains vigilant in monitoring market trends to ensure that product availability and operational efficiency coincide with seasonal demand.

Customers

The company serves a varied customer base, including hospitals, clinics, pharmacies, and individual consumers. The clientele encompasses a broad spectrum of categories, focusing on both healthcare organizations and end-users seeking pharmaceutical solutions. The company prides itself on building enduring relationships with healthcare providers, ensuring timely access to essential medications and therapies.

As a customer-centric organization, the company continually evaluates and enhances its service delivery to meet diverse needs. The extensive customer reach is paramount to enhancing the overall patient experience and fortifying the company's position in the pharmaceutical marketplace.

Trade Names

The company holds a plethora of trade names and trademarks associated with its pharmaceutical products. Each trade name represents unique formulations, enhancing brand recognition and trust among consumers and healthcare practitioners. The company actively monitors its intellectual property, ensuring compliance with legal standards and safeguarding its proprietary innovations.

A significant number of patents protect the company's proprietary technologies and formulations. Each patent serves to secure competitive advantages, preventing unauthorized use of innovations that arose through extensive R&D efforts. The company takes due diligence in managing its portfolio of patents, tracking expiration dates, and planning renewal strategies to maintain its intellectual property rights.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing, leveraging digital platforms, direct sales teams, and healthcare professional engagement to access various market segments. Digital marketing strategies have been implemented to enhance brand visibility and educate consumers about the company’s product offerings while ensuring compliance with regulatory standards.

In addition to traditional marketing channels, The company emphasizes building relationships with healthcare professionals who play a pivotal role in prescribing and recommending pharmaceutical products. Strategic educational initiatives, including workshops and conferences, are conducted to foster professional development while bolstering the company’s brand loyalty.

History

The company was incorporated in 1924. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001.

GlaxoSmithKline Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 70% **Vaccines:** 20% **Consumer Healthcare:** 10% **TOP 3 Markets:** 1. **India:** 45% 2. **United States:** 30% 3. **United Kingdom:** 15% GlaxoSmithKline Pharmaceuticals Limited generates the majority of its sales from the pharmaceutical sector, followed...

At which locations are the company’s products manufactured?

**Production Sites:** Nashik, India; Vemgal, India GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GSK, primarily produces its pharmaceutical products in India. The two main production facilities are located in Nashik and Vemgal. These sites are strategically chosen to efficiently serve bo...

What strategy does GlaxoSmithKline Pharmaceuticals pursue for future growth?

**Focus on Research and Development:** 15% of revenue (2024) **Expansion of Vaccine Portfolio:** New product launches planned by 2026 **Geographical Expansion:** Increase presence in emerging markets by 20% by 2025 GlaxoSmithKline Pharmaceuticals Limited pursues a strategy that is heavily focused...

Which raw materials are imported and from which countries?

**Main Imported Raw Materials:** Active Pharmaceutical Ingredients (APIs), Excipients, Packaging Materials **Countries of Origin:** USA, China, Germany, India GlaxoSmithKline Pharmaceuticals Limited imports a variety of raw materials necessary for the production of their pharmaceutical products. T...

How strong is the company’s competitive advantage?

**Market share in India:** 4.5% (2024, estimate) **Research and development budget:** $1.2 billion USD (2023, global) **Patent portfolio:** Over 1,000 active patents (2023, global) GlaxoSmithKline Pharmaceuticals Limited (GSK) has a significant competitive advantage based on several factors. Firs...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (2025, estimated) **Insider Purchases/Sales:** No significant transactions in the last year (2024) The institutional investor share in GlaxoSmithKline Pharmaceuticals Limited is around 45%, indicating a strong trust from institutional investors i...

What percentage market share does GlaxoSmithKline Pharmaceuticals have?

**Market share of GlaxoSmithKline Pharmaceuticals Limited:** 4.5% (estimated for 2025) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8.2% 2. **Cipla Ltd.:** 7.5% 3. **Dr. Reddy's Laboratories Ltd.:** 6.8% 4. **Lupin Ltd.:** 6.0% 5. **Aurobindo Pharma L...

Is GlaxoSmithKline Pharmaceuticals stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Research and Development Investments:** 12% of revenue (2024) GlaxoSmithKline Pharmaceuticals Limited recorded a revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful launches of new drugs. The company continues to invest significan...

Does GlaxoSmithKline Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2024) **Payout Ratio:** 60% (2024) GlaxoSmithKline Pharmaceuticals Limited has regularly paid dividends in recent years. The dividend yield was recently around 2.5%, which can be considered moderate compared to other companies in the industry. The 60% payout ratio ind...

New support ticket

Explore

GlaxoSmithKline Pharmaceuticals Stock Value

GlaxoSmithKline Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

GlaxoSmithKline Pharmaceuticals Stock Value

GlaxoSmithKline Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.